NBIX News and Press, Neurocrine Biosciences Inc. From 10/31/23

Tennant Company (TNC) is expected to report for Q3 2023 Stellantis N.V. (STLA) is expected to report for Q3 2023 Marathon Petroleum Corporation (MPC) is expected to report $7.79 for Q3 2023 Easterly Government Properties Inc. (DEA) is expected to report $0.29 for Q3 2023 Allegion ...

Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $486 Million Representing 29% Year-Over-Year Growth INGREZZA ® ...

Neurocrine Biosciences Inc. (NBIX) is expected to report $0.9 for Q3 2023

2023-10-30 12:34:24 ET More on Neurocrine Biosciences Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impres...

2023-10-11 03:44:41 ET Summary Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. The adult study showed that 63% of patients on crinecerfont were able to reduce their steroid usage to physiol...

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results PR Newswire Conference Call and Webcast Scheduled for Tuesday, October 31 SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasd...

2023-10-05 22:21:27 ET Summary I argue that financial professionals should pay more attention to large-cap stocks outside the S&P 500, as they often offer missed opportunities for investors. The S&P 500 is not a purely passive index, as it is actively managed and has speci...

Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints PR Newswire CAHtalyst ™ Pediatric Study Met Primary Endpo...

Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023 PR Newswire SAN DIEGO , Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analy...

2023-09-14 08:54:47 ET More on Neurocrine Seeking Alpha’s Quant Rating on Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Eff...